Zentalis Pharmaceuticals, Inc. Income Statement

Income Statement Dec2019 Dec2020 Dec2021 Dec2022 Dec2023 Dec2024
Revenue & cost
Revenue 67.42M
Operating items
Research & Development 38.39M84.90M175.60M172.73M189.59M167.77M
Selling, General & Administrative 8.46M33.89M40.94M54.55M64.35M87.11M
Other Operating Expenses 45.57M3.74M
Operating Expenses 46.84M118.79M216.54M227.29M299.51M258.62M
Operating Income -46.84M-118.79M-216.54M-227.29M-299.51M-191.19M
EBIT -46.84M-118.79M-216.54M-227.29M-299.51M-191.19M
Non-operating items
Interest & Investment Income 0.48M0.68M0.40M5.99M22.62M25.50M
Net income details
EBT -46.36M-118.10M-164.56M-221.30M-276.89M-165.69M
Tax Provisions 0.01M0.44M-0.30M-0.47M-0.60M0.18M
Profit After Tax -46.38M-118.55M-166.09M-237.11M-292.31M-165.87M
Equity Income -1.83M-16.28M-16.01M
Net Income - Minority -0.22M-0.11M
Income from Non-Controlling Interests -0.71M-0.71M-7.37M-0.31M-0.11M-0.03M
Income from Continuing Operations -46.38M-118.55M-164.26M-220.83M-276.29M-165.87M
Consolidated Net Income -46.38M-118.55M-164.26M-220.83M-276.29M-165.87M
Income towards Parent Company -46.38M-118.55M-164.26M-221.05M-276.40M-165.87M
Net Income towards Common Stockholders -46.38M-118.55M-164.26M-221.05M-276.40M-165.87M
Additional items
EPS (Basic) -8.16-4.19-3.72-4.48-4.47-2.33
EPS (Weighted Average and Diluted) -8.16-4.19-3.72-4.48-4.47-2.33
Shares Outstanding (Weighted Average) 32.87M40.61M45.56M57.07M70.96M71.81M
Shares Outstanding (Diluted Average) 52.86M65.41M71.08M
EBITDA -46.84M-118.79M-216.54M-227.29M-299.51M-191.19M
Shares Outstanding 59.28M70.77M
Tax Rate 0.180.210.22